How Should Functional Medicine Interpret Homocysteine?

← Back to Clinical Articles

Article: How Should Functional Medicine Interpret Homocysteine?  |  Category: Lab Interpretation  |  Authored by: Brian Lamkin, DO

What Homocysteine Is and Why It Accumulates

Homocysteine is a sulfur-containing amino acid produced as an intermediate in the methylation cycle. It is not obtained from diet. It is produced when methionine (an essential amino acid from dietary protein) donates its methyl group through S-adenosylmethionine (SAMe) to the hundreds of methylation reactions that regulate gene expression, neurotransmitter production, detoxification, DNA repair, and cellular signaling^[1]. After donating its methyl group, methionine becomes homocysteine. Homocysteine must then be recycled through one of two pathways: remethylation back to methionine (requiring methylfolate from the MTHFR enzyme and methylcobalamin as a cofactor) or transsulfuration to cysteine (requiring pyridoxal-5-phosphate, active vitamin B6). When either pathway is impaired, homocysteine accumulates. Elevated homocysteine is therefore not a disease in itself. It is a functional readout indicating that the methylation cycle is not working efficiently, and the cause of the impairment determines the treatment.

The Conventional vs. Functional Range

The conventional reference range for homocysteine is typically 5 to 15 micromol/L, with some labs using an upper limit of 12. Conventional medicine generally does not intervene until homocysteine exceeds 15, and even then the response is often a simple recommendation to "take B vitamins" without dosing specificity or follow-up testing. Functional medicine uses a significantly tighter target: below 8 micromol/L, with an optimal range of 6 to 8. This tighter range is supported by research demonstrating that cardiovascular risk increases progressively above 8, that every 5-unit increase in homocysteine above 8 is associated with approximately 25 percent increased cardiovascular event risk, that homocysteine above 10 is associated with accelerated cognitive decline and increased dementia risk^[2], and that neural tube defect risk begins increasing at maternal homocysteine levels above 10 despite being "within normal limits." A patient with a homocysteine of 12 is told it is normal by conventional standards. By functional standards, that value represents impaired methylation capacity with elevated cardiovascular and neurological risk.

What Drives Homocysteine High

The most common causes of elevated homocysteine in clinical practice are B12 deficiency (methylcobalamin is the cofactor for methionine synthase, the enzyme that remethylates homocysteine to methionine; B12 deficiency impairs this reaction directly), folate deficiency or MTHFR polymorphism (the MTHFR enzyme converts dietary folate to 5-methyltetrahydrofolate, the active form that provides the methyl group for homocysteine remethylation; MTHFR C677T homozygous reduces enzyme activity by approximately 70 percent^[3]), B6 deficiency (pyridoxal-5-phosphate is the cofactor for the transsulfuration pathway; B6 deficiency impairs the alternative homocysteine clearance route), hypothyroidism (thyroid hormones regulate the expression of methylation enzymes; even subclinical hypothyroidism can elevate homocysteine), renal impairment (the kidneys are a major site of homocysteine clearance), and medications including methotrexate (antifolate), anticonvulsants (deplete folate), and metformin (depletes B12 over time).

Homocysteine and Cardiovascular Risk

Elevated homocysteine damages the vascular endothelium through direct oxidative stress, promotes smooth muscle cell proliferation in arterial walls, activates inflammatory pathways in the vasculature, impairs nitric oxide production (reducing vasodilation capacity), and promotes a prothrombotic state by activating coagulation factors and inhibiting natural anticoagulant mechanisms^[1]. These mechanisms make elevated homocysteine an independent cardiovascular risk factor that is additive to traditional risk factors (LDL, blood pressure, smoking, diabetes). The clinical significance: a patient with "normal" LDL and "normal" blood pressure but a homocysteine of 14 has a vascular risk factor that standard screening missed. When homocysteine is evaluated alongside hs-CRP, oxidized LDL, Lp-PLA2, and triglyceride:HDL ratio, the complete inflammatory and metabolic cardiovascular risk profile emerges.

Homocysteine and Neurological Health

The relationship between elevated homocysteine and cognitive decline is among the most consistent findings in neurology research^[2]. Homocysteine above 10 is associated with accelerated brain atrophy (particularly in the hippocampus and medial temporal lobe), increased risk of Alzheimer's disease and vascular dementia, impaired neurotransmitter synthesis (methylation is required for serotonin, dopamine, and norepinephrine production), and reduced BDNF (brain-derived neurotrophic factor) expression. The mechanism is bidirectional: elevated homocysteine causes direct neurotoxicity through NMDA receptor activation and oxidative stress, and impaired methylation (which the elevated homocysteine reflects) reduces the methylation reactions required for neurotransmitter synthesis, myelin maintenance, and epigenetic regulation of neuronal gene expression. In patients presenting with cognitive decline, brain fog, or depression, homocysteine evaluation is essential because it identifies a treatable driver that responds to targeted B-vitamin supplementation.

Methylation: What Homocysteine Really Reflects

Homocysteine is clinically valuable not because the molecule itself causes disease (though it does contribute to vascular and neurological damage at high levels) but because it is a window into the functional status of the methylation cycle. Methylation is one of the most important biochemical processes in the body: it regulates gene expression through DNA methylation (epigenetic control), produces and metabolizes neurotransmitters (serotonin, dopamine, norepinephrine, melatonin), detoxifies hormones (estrogen methylation is a critical step in hormone clearance), produces glutathione (the master antioxidant) through the transsulfuration pathway, maintains myelin sheaths on neurons, repairs DNA, and produces phosphatidylcholine for cell membrane integrity. When homocysteine is elevated, it means the methylation cycle is not turning efficiently, and all of these downstream processes are compromised to some degree. This is why elevated homocysteine correlates with such a wide range of clinical problems: it is not that homocysteine causes all of them directly, but that the methylation impairment it reflects affects virtually every system.

MTHFR: The Genetic Variable

The MTHFR gene encodes the enzyme methylenetetrahydrofolate reductase, which converts dietary folate to 5-methyltetrahydrofolate (5-MTHF), the active form that provides the methyl group for homocysteine remethylation^[3]. Two common polymorphisms affect enzyme function: C677T (homozygous reduces activity by approximately 70 percent, heterozygous by approximately 35 percent) and A1298C (milder reduction, clinically significant mainly in compound heterozygotes C677T/A1298C). The clinical significance of MTHFR polymorphisms is frequently overstated in functional medicine circles. Having an MTHFR polymorphism does not guarantee elevated homocysteine or methylation problems. Adequate folate intake (particularly as methylfolate rather than folic acid, which requires MTHFR to convert) can compensate for reduced enzyme activity. The most clinically useful approach: test homocysteine directly (which measures the functional output of the entire methylation system) rather than relying on MTHFR genotyping alone. If homocysteine is elevated, treat with methylfolate regardless of MTHFR status. If homocysteine is optimal, the methylation system is functioning adequately regardless of MTHFR genotype.

How to Lower Homocysteine

Targeted B-vitamin supplementation is the primary intervention^[4]. Methylfolate (L-5-MTHF): 1 to 5mg daily. This is the active form that bypasses the MTHFR enzyme entirely, making it effective regardless of MTHFR genotype. Folic acid (the synthetic form in most supplements and fortified foods) requires MTHFR conversion and is less effective in patients with MTHFR polymorphisms. Methylcobalamin (B12): 1000 to 5000mcg daily, sublingual or injectable. The methylated form is preferred because it directly provides the methyl group for the methionine synthase reaction. Cyanocobalamin (the most common supplement form) requires conversion to methylcobalamin and may be less effective. Pyridoxal-5-phosphate (active B6): 25 to 50mg daily. Supports the transsulfuration pathway. Riboflavin (B2): 25 to 50mg daily. B2 is a cofactor for the MTHFR enzyme itself, and supplementation can improve MTHFR function even in patients with the C677T polymorphism. Betaine (trimethylglycine, TMG): 500 to 3000mg daily. Provides an alternative homocysteine remethylation pathway through betaine-homocysteine methyltransferase (BHMT), independent of the folate/MTHFR pathway. Particularly useful when homocysteine does not respond adequately to B-vitamins alone.

The Thyroid Connection

Thyroid hormones regulate the expression of methylation enzymes, and hypothyroidism is a frequently overlooked cause of elevated homocysteine. When Free T3 is low (even in the "normal" range), methylation enzyme activity is reduced and homocysteine accumulates. This means that B-vitamin supplementation alone may not normalize homocysteine in a patient with concurrent thyroid underfunction. The clinical approach: evaluate thyroid status (TSH, Free T3, Free T4) alongside homocysteine. If both are suboptimal, thyroid optimization must accompany B-vitamin supplementation for homocysteine to normalize. This connection is commonly missed when homocysteine and thyroid are evaluated by different providers who do not integrate the results.

Monitoring Response

Homocysteine responds to targeted supplementation within 8 to 12 weeks. Retest at 3 months after initiating the B-vitamin protocol. If homocysteine has not improved: verify compliance (the most common cause of non-response), evaluate B12 absorption (consider sublingual or injectable B12 if oral is not producing improvement, particularly in patients with hypochlorhydria or gut permeability), evaluate thyroid status, consider adding betaine (TMG) if the folate/B12 pathway alone is insufficient, check renal function (elevated creatinine impairs homocysteine clearance), and review medications that may be competing with B-vitamin status. Once target is achieved (below 8), maintenance supplementation continues indefinitely because the underlying factors (MTHFR polymorphisms, dietary patterns, absorption capacity) are typically permanent.

The Lamkin Clinic Approach

Homocysteine is included in the standard metabolic and cardiovascular assessment at The Lamkin Clinic. It is evaluated alongside hs-CRP (systemic inflammation), fasting insulin (metabolic health), triglyceride:HDL ratio (metabolic cardiovascular risk), oxidized LDL and Lp-PLA2 (vascular inflammation), Free T3 (thyroid-methylation connection), and vitamin D (immune and bone health). When homocysteine is elevated, targeted B-vitamin supplementation is initiated with methylfolate, methylcobalamin, P5P, riboflavin, and betaine as indicated. Concurrent thyroid evaluation ensures that thyroid underfunction is not preventing methylation normalization. Follow-up testing at 3 months confirms response and guides dose adjustment. The goal is not simply "lowering a number." The goal is restoring the methylation capacity that regulates gene expression, neurotransmitter production, hormone clearance, and detoxification.

The Lamkin Clinic, Edmond Oklahoma | lamkinclinic.com

Frequently Asked Questions

Related Conditions

Related Clinical Articles

References and Further Reading

1. [1]Humphrey LL, et al. Homocysteine level and coronary heart disease incidence: a systematic review and meta-analysis. Mayo Clin Proc. 2008;83(11):1203-1212.
2. [2]Smith AD, et al. Homocysteine and dementia: an international consensus statement. J Alzheimers Dis. 2018;62(2):561-570.
3. [3]Liew SC, Gupta ED. Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism: epidemiology, metabolism and the associated diseases. Eur J Med Genet. 2015;58(1):1-10.
4. [4]Clarke R, et al. Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality. Arch Intern Med. 2010;170(18):1622-1631.